Company Shares of United Therapeutics Corporation (NASDAQ:UTHR) Rally 2.08%

United Therapeutics Corporation (NASDAQ:UTHR) has been under a strong bear grip, hence the stock is down -1.76% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.79% in the past 1 week. The stock has risen by 2.08% in the past week indicating that the buyers are active at lower levels, but the stock is down -0.17% in the past 4 weeks.

The company shares have dropped -35.42% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $181.03 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $110.39 and the 200 Day Moving Average price is recorded at $120.58.

The stock has recorded a 20-day Moving Average of 5.03% and the 50-Day Moving Average is 0.83%.


United Therapeutics Corporation (NASDAQ:UTHR): stock turned positive on Friday. Though the stock opened at $109.44, the bulls momentum made the stock top out at $111.87 level for the day. The stock recorded a low of $109.38 and closed the trading day at $111.16, in the green by 1.44%. The total traded volume for the day was 652,774. The stock had closed at $109.58 in the previous days trading.

In an insider trading activity,The director officer (Chairman & CEO) of United Therapeutics Corp, Rothblatt Martine A sold 1,293 shares at $110.02 on July 7, 2016. The Insider selling transaction had a total value worth of $142,256. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Companys key therapeutic products and product candidates include Remodulin, Tyvaso (treprostinil), Adcirca (tadalafil), Remodulin Implantable System, Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation, for the treatment of End-stage lung disease; UV-4B, for the treatment of Dengue and influenza, and Glycobiology Antiviral Agents, for the treatment of a spectrum of agents against viral infectious diseases, among others. The Companys lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.